After a number of delays it is no surprise the market is sceptical and is discounting the share. A few milestones hit and this will be a different story SP wise
The 'other diagnostic Pamela's is why I have stayed here this long. With nipt shortly turning a profit the additional products (cancer screening?) will turn us into a far bigger player and target for TF
His comments was that long term it was worth holding on but that in the short term there were better places to put your money. As HSR focuses on trading and shorter term opportunities he thought it didn't belong in that portfolio for the time being
Unfortunately it won't go anywhere quickly as there will be the overhang from all the flippers at 7p as soon as this gets into double figures. We'll have to wait a while for them to sell out and move on
I do think that the relationship between TW and AR is unhealthy and that TW certainly gets preferential treatment for platings and that this clouds his judgement.
I do think that AR is a good deal maker and that he pulled off a good one with Yourgene